Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100, following Merck’s (MRK) $10B proposal to acquire all Verona for $107 per share or $10B. Verona’s Ohtu makes sense as the “anchor” drug to help grow Merck’s existing footprint in respiratory franchise and be competitive against dupi, IL33s and more, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma downgraded to Neutral from Buy at BTIG
- Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo